{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T21:19:17Z","timestamp":1720300757444},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,3,11]],"date-time":"2012-03-11T00:00:00Z","timestamp":1331424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00401-012-0967-7","type":"journal-article","created":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T14:45:42Z","timestamp":1331390742000},"page":"751-752","source":"Crossref","is-referenced-by-count":12,"title":["Natalizumab-associated complication? First case of peripheral T cell lymphoma"],"prefix":"10.1007","volume":"123","author":[{"given":"Jeffrey","family":"Schowinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Corboy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. K.","family":"Kleinschmidt-DeMasters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,11]]},"reference":[{"key":"967_CR1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1177\/1352458509347154","volume":"15","author":"R Bergamaschi","year":"2009","unstructured":"Bergamaschi R, Montomoli C (2009) Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler 15:1532\u20131533","journal-title":"Mult Scler"},{"key":"967_CR2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ana.21630","volume":"65","author":"JR Berger","year":"2009","unstructured":"Berger JR, Houff S (2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 65:367\u2013377","journal-title":"Ann Neurol"},{"key":"967_CR3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, DeLuca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438\u2013446","journal-title":"Lancet Neurol"},{"key":"967_CR4","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.3949\/ccjm.78.s2.08","volume":"78","author":"R Fox","year":"2011","unstructured":"Fox R (2011) Advances in the management of PML: focus on natalizumab. Cleve Clin J Med 78:S33\u2013S37","journal-title":"Cleve Clin J Med"},{"key":"967_CR5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00415-009-5200-9","volume":"256","author":"A Ismail","year":"2009","unstructured":"Ismail A, Kemp J, Sharrack B (2009) Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis. J Neurol 256:1771\u20131772","journal-title":"J Neurol"},{"key":"967_CR6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369\u2013374","journal-title":"N Engl J Med"},{"key":"967_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","volume":"9","author":"DS Kotlyar","year":"2011","unstructured":"Kotlyar DS, Osterman MT, Diamond RH et al (2011) A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 9:36\u201341","journal-title":"Clin Gastroenterol Hepatol"},{"key":"967_CR8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"967_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10072-010-0427-x","volume":"32","author":"A Laroni","year":"2011","unstructured":"Laroni A, Bedognetti M, Uccelli A et al (2011) Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 32:181\u2013182","journal-title":"Neurol Sci"},{"key":"967_CR10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMc0706103","volume":"358","author":"JT Mullen","year":"2008","unstructured":"Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358:647\u2013648","journal-title":"N Engl J Med"},{"key":"967_CR11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJMc086089","volume":"359","author":"MA Panzara","year":"2008","unstructured":"Panzara MA, Bozic C, Sandrock AW (2008) More on melanoma with transdifferentiation. N Engl J Med 359:99","journal-title":"N Engl J Med"},{"key":"967_CR12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"967_CR13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21782","volume":"66","author":"A Schweikert","year":"2009","unstructured":"Schweikert A, Kremer M, Ringel F et al (2009) Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 66:403\u2013406","journal-title":"Ann Neurol"},{"key":"967_CR14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181beed38","volume":"73","author":"O Stuve","year":"2009","unstructured":"Stuve O, Wiendl H (2009) Iatrogenic immunosuppression with biologics in MS: expecting the unexpected? Neurology 73:1346\u20131347","journal-title":"Neurology"},{"key":"967_CR15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"967_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1352458510389629","volume":"17","author":"BM Vavricka","year":"2010","unstructured":"Vavricka BM, Baumberger P, Russmann S, Kullak-Ublick GA (2010) Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler 17:255\u2013256","journal-title":"Mult Scler"},{"key":"967_CR17","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.0b013e3181bd114f","volume":"73","author":"C Zecca","year":"2009","unstructured":"Zecca C, Nessi F, Bernasconi E, Gobbi C (2009) Ocular toxoplasmosis during natalizumab treatment. Neurology 73:1418\u20131419","journal-title":"Neurology"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-012-0967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-012-0967-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-012-0967-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T17:24:14Z","timestamp":1559064254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-012-0967-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,11]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s00401-012-0967-7","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,11]]}}}